Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thrombosis, pregnancy complications and other non-thrombotic manifestations in the presence of antiphospholipid antibodies (aPL). Since its identification in 1983, research on APS has progressed, but no targeted therapies other than anticoagulation are yet available, with a mortality rate of 9.3% after a 10-year follow-up. Objective: The aim of the current systematic literature reviews (SLRs) is to identify and compare upregulated proteins in patients with thrombotic APS (tAPS) and non-aPL thrombosis, thereby providing useful insights into APS pathogenesis. Methods: We conducted two SLRs in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify proteins upregulated in tAPS and non-aPL-related thrombosis. Eligible studies included observational controlled research and focused on proteomics. Gene Ontology (GO) enrichment and network analyses were performed on the identified proteins. Results: Of 108 and 209 records identified, seven and 13 were included in the SLR for tAPS and non-aPL thrombosis, respectively. The review identified 118 upregulated proteins in tAPS and 319 in non-aPL-related thrombosis. GO analysis revealed distinct biological process enrichment: platelet aggregation, platelet activation and blood coagulation were predominant in tAPS, while haemostasis, coagulation and wound healing were central in non-aPL-related thrombosis. Molecular functions in tAPS centred on receptor and protein complex binding, while enzymatic activities dominated in non-aPL thrombosis. Conclusion: Our findings highlight the central role of platelet-related processes in tAPS pathogenesis, distinguishing it from non-aPL thrombosis. By elucidating the unique proteomic and functional characteristics of tAPS, this study provides a foundation for future research into targeted therapies that address platelet involvement in APS pathogenesis.
23 September 2025 in Clinical and Experimental Rheumatology
This case-control study aimed to elucidate the prevalence and role as biomarker of anti-neutrophil extracellular trap (anti-NET) antibodies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (SSc). Serum samples from SLE, RA, SSc and healthy donors (HD) were evaluated for anti-NETs IgG, using an ELISA home-made coated with phorbol myristate acetate (PMA)-induced NET. Based on a positivity threshold set at the 99th percentile for HD sera, we calculated the positive samples. We enrolled 349 patients with autoimmune rheumatic diseases (ARD), finding a prevalence of anti-NETs of about 40%. Of the 136 SLE patients 50 (36.8%) were anti-NETs positive, revealing an association between anti-NETs and antiphospholipid syndrome (APS) (OR 3.37 [95% CI 1.22-9.36], p=0.02) and with arterial thrombosis regardless of coexisting APS (OR 5.52 [95% CI 1.07-28.52], p=0.032). In RA patients 52 out 131 (39.7%) tested positive for anti-NETs and we found a significant association between testing positive for anti-NETs and the presence of ACPA (p=0.049). Of the 82 SSc patients enrolled 33 (40%) were anti-NETs positive, and we found a direct correlation with CCL-18 (r 0.289 [CI 95% 0.04-0.50], p=0.02), a biomarker of worst prognosis and mortality in ILD-SSc patients. In SLE patients, anti-NETs could have a role as a biomarker of thrombosis, a major cause of mortality in SLE.
This study, involving a cohort of 980 patients with arterial and/or venous events, evaluated the relative importance of genetic and traditional risk factors using a machine learning model approach. The analysis revealed that conventional risk factors—such as age, gender, tobacco use, obesity—and acquired thrombophilia (most prominently antiphospholipid syndrome [APS]) outperformed any genetic risk variants analyzed. Of note, the presence of heterozygous FVL mutations was associated with a reduced arterial risk, whereas carriers of heterozygous factor VII activation protease (FSAP) mutations had a lower risk of venous events.Thus, by employing diverse statistical approaches, the study showed that acquired risk factors exert the most substantial impact on the development of thrombotic events, except for the well-known role of FVL mutations in venous events.
Cerebrovascular events (CE) are one of the most common and severe events in antiphospholipid syndrome (APS), a condition characterized by thrombosis and circulating anti-phospholipid antibodies (aPL). Seronegative APS (SN-APS) refers to a group of patients with clinical features of APS but persistently negative tests for “criteria aPL”: anti-cardiolipin antibodies (aCL) and anti-β2glycoprotein I antibodies detected by enzyme-linked immunosorbent assay (ELISA), and the lupus anticoagulant detected by clotting assays. We report a series of five cases of SN-APS in young or middle-aged patients who tested positive for “non-criteria” aPL. We retrospectively collected cases of SN-APS patients who experienced CE without an identified cause despite an extensive diagnostic work-up and tested negative for criteria aPL. All the patient sera were tested for aCL by immunostaining on thin-layer chromatography (TLC) and anti-vimentin/cardiolipin (aCL/Vim) by ELISA. We identified five cases of female patients aged 21 to 58 years, evaluated at the Rheumatology Unit and/ or Stroke Unit/Emergency Department of the Sapienza University Hospital of Rome, “Policlinico Umberto I”. All patients presented a clinical history suggestive of APS. All the patients tested positive for aCL by TLC-immunostaining, and one patient was positive for aCL/Vim. In young or middle-aged patients with cryptogenic CE and a clinical history suggestive of APS, the use of new diagnostic tools for identifying aPL, if validated in future studies, could represent an important step in the prompt diagnosis of APS.